McLean Asset Management Corp Buys 302 Shares of Lam Research Co. (NASDAQ:LRCX)

McLean Asset Management Corp increased its stake in shares of Lam Research Co. (NASDAQ:LRCX) by 6.3% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,122 shares of the semiconductor company’s stock after acquiring an additional 302 shares during the period. McLean Asset Management Corp’s holdings in Lam Research were worth $370,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of LRCX. Quarry LP increased its position in Lam Research by 175.0% during the second quarter. Quarry LP now owns 88 shares of the semiconductor company’s stock worth $94,000 after buying an additional 56 shares during the last quarter. NCP Inc. acquired a new position in Lam Research during the second quarter worth approximately $213,000. Migdal Insurance & Financial Holdings Ltd. grew its position in shares of Lam Research by 2,400.0% in the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 200 shares of the semiconductor company’s stock valued at $163,000 after purchasing an additional 192 shares during the last quarter. Advisory Alpha LLC acquired a new position in shares of Lam Research in the second quarter valued at approximately $256,000. Finally, Silver Lake Advisory LLC acquired a new position in shares of Lam Research in the second quarter valued at approximately $261,000. Institutional investors own 84.61% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on LRCX. Mizuho decreased their target price on Lam Research from $95.00 to $90.00 and set an “outperform” rating on the stock in a research report on Friday, January 10th. Morgan Stanley upped their target price on Lam Research from $76.00 to $78.00 and gave the company an “equal weight” rating in a research report on Thursday, December 5th. B. Riley decreased their target price on Lam Research from $132.50 to $105.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. The Goldman Sachs Group reduced their price target on Lam Research from $96.00 to $85.00 and set a “buy” rating on the stock in a research report on Friday, January 10th. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $100.00 price target on shares of Lam Research in a research report on Thursday, October 24th. Nine equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat, Lam Research currently has an average rating of “Moderate Buy” and a consensus price target of $95.77.

Lam Research Trading Down 1.9 %

NASDAQ LRCX opened at $79.68 on Monday. The company has a quick ratio of 1.74, a current ratio of 2.53 and a debt-to-equity ratio of 0.53. Lam Research Co. has a twelve month low of $68.87 and a twelve month high of $113.00. The company has a market cap of $102.52 billion, a price-to-earnings ratio of 25.75, a price-to-earnings-growth ratio of 1.53 and a beta of 1.45. The business’s fifty day moving average is $75.43 and its 200 day moving average is $79.63.

Lam Research Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, January 8th. Investors of record on Wednesday, December 11th were issued a dividend of $0.23 per share. This represents a $0.92 annualized dividend and a dividend yield of 1.15%. The ex-dividend date was Wednesday, December 11th. Lam Research’s dividend payout ratio (DPR) is 29.74%.

Lam Research Profile

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products.